| VERASTEM INC. NEW |
| USA |
| Gesundheit |
| US92337C2035 / A3EHM3 |
| 2VSA (Frankfurt) / VSTM (NASDAQ) |
| FRA:2VSA, ETR:2VSA, 2VSA:GR, NASDAQ:VSTM |
| - |
| https://www.verastem.com/ |
|
Verastem Inc. is a biopharmaceutical company that concentrates on developing and commercializing innovative cancer therapies. Its primary focus is on creating treatments targeting cancer cell survival and division pathways, specifically in hematologi..
>Volltext.. |
| 368.33 Mio. EUR |
| 268.91 Mio. EUR |
| 26.73 Mio. EUR |
| -146.47 Mio. EUR |
| -181.11 Mio. EUR |
| -2.68 EUR |
| 75.37 Mio. EUR |
| 177.24 Mio. EUR |
| -118.89 Mio. EUR |
| 2.84 |
| 172.48% |
| -41.33% |
| - |
| - |
| - |
| - |
| VERASTEM |
| 01.04.26 |
|